Prasugrel Hydrochloride Patent Expiration
Prasugrel Hydrochloride is Used for preventing thrombosis and embolisms in patients at risk of thrombotic cardiovascular events. It was first introduced by Cosette Pharmaceuticals Inc
Prasugrel Hydrochloride Patents
Given below is the list of patents protecting Prasugrel Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Effient |
US8404703 (Pediatric) | Medicinal compositions containing aspirin |
Jul 02, 2023
(Expired) | Cosette |
| Effient |
US8569325 (Pediatric) | Method of treatment with coadministration of aspirin and prasugrel |
Jul 02, 2023
(Expired) | Cosette |
| Effient | US8569325 | Method of treatment with coadministration of aspirin and prasugrel |
Jan 02, 2023
(Expired) | Cosette |
| Effient | US8404703 | Medicinal compositions containing aspirin |
Mar 02, 2022
(Expired) | Cosette |
| Effient | US6693115 | Acid addition salts of hydropyridine derivatives |
Jul 03, 2021
(Expired) | Cosette |
| Effient |
US5288726 (Pediatric) | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Oct 14, 2017
(Expired) | Cosette |
| Effient | US5288726 | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Apr 14, 2017
(Expired) | Cosette |
Prasugrel Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Prasugrel Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy | Columbia University | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE3 |